Skip to main content
. 2016 Jul 27;6:30377. doi: 10.1038/srep30377

Figure 5. Comparison of hepatotoxicity and knockdown activity using a gapmer with GalNAc3-siRNA.

Figure 5

(a) Schematic of GalNAc3-siRNA. The siRNA was designed to target almost same position of Acsl1 mRNA as does the gapmer. To avoid degradation, 2′-fluoro- (2′F) and 2′-O-methyl (2′OMe) nucleotides were utilized. (b) Structure of GalNAc3 probe. (c) Acls1 mRNA level. Administration of GalNAc3-siRNA resulted in almost the same level of knockdown as 5 mg/kg/day of gapmer. (d) Plasma ALT and (e) AST levels. (f) Expression profile of cytokines. (n = 3, mean + S.D., *p < 0.01, Mann–Whitney U test, vs saline).